The evolving immune ecosystem of TKI resistance in EGFR-mutant NSCLC: from treatment-induced remodeling to mechanism-guided therapy
Tyrosine kinase inhibitors (TKIs) have transformed the treatment of EGFR-mutant non-small cell lung cancer (NSCLC), yet acquired resistance remains a major clinical limitation. Resistance is increasingly understood as an evolving state shaped not only by tumor-cell genomic alterations but also by treatment-induced remo...